Clinical Considerations in Contraceptive Choice and Use of Low-Dose Estrogen Formulation
Panelists discuss how combined hormonal contraceptives come in three main forms (pills, patches, and rings) and provide a comprehensive overview of all available contraceptive methods including long-acting reversible contraceptives, barrier methods, and emergency contraception.
Video content above is prompted by the following:
This segment provides a foundational overview of contemporary contraceptive methods available to women, with particular emphasis on combined hormonal contraceptives. Dr. Anita Nelson and Dr. Kathleen Morrell introduce the three primary forms of combined hormonal contraceptives available in the United States: vaginal rings, transdermal patches, and oral contraceptive pills. These methods combine both estrogen and progestin components, offering women multiple delivery systems with varying administration schedules - from daily pills to weekly patches to monthly rings.
The discussion expands to cover the complete spectrum of contraceptive options, including long-acting reversible contraceptives (LARCs) such as intrauterine devices and implants. Healthcare providers learn about both hormonal and non-hormonal IUDs, with hormonal versions containing levonorgestrel that thickens cervical mucus to prevent sperm entry, while copper IUDs work through spermicidal action. The segment also addresses shorter-term options like Depo-Provera injections and barrier methods, providing a comprehensive menu of choices for different patient needs.
Emergency contraception, permanent sterilization, and emerging technologies like digital fertility monitoring devices round out the contraceptive landscape. The experts emphasize the importance of offering diverse options to accommodate varying patient preferences, lifestyles, and medical considerations. This foundational knowledge enables healthcare providers to better counsel patients on the full range of available contraceptive methods, ensuring informed decision-making that aligns with individual patient goals and circumstances.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Impact of endometrial thickness and abnormal uterine bleeding on endometrial cancer
August 1st 2025A prospective observational study has assessed the clinical relevance of endometrial thickness and abnormal uterine bleeding to endometrial cancer risk in a cohort of postmenopausal patients undergoing diagnostic hysteroscopy and endometrial biopsy.
Read More
Legally Speaking: Did contraindicated hysterectomy lead to HIT and limb loss?
August 1st 2025The patient had a history of fibroid uterus and dilated pelvic vessels in the left adnexal region, obscuring the left ovary. On April 2, 2014, the patient was seen as a gyn outpatient at the clinic by Defendant OB. The patient complained it caused her urinary tract irritative symptoms and back pain. An MRI was ordered for evaluation. A 9.9cm exophytic fibroid arising from the posterior uterine body with focal cystic degeneration was seen.
Read More
